IMMUNOHISTOCHEMISTRY, CD 20

The IHC – CD20 (Cluster of Differentiation 20) test is an immunohistochemistry-based diagnostic assay used to detect CD20 protein expression in tissue samples. CD20 is a surface antigen primarily found on B-lymphocytes, making it one of the most important markers for identifying B-cell lineage in hematopathology.

This test is widely used in pathology and oncology to diagnose and classify B-cell lymphomas, leukemias, and other lymphoproliferative disorders. CD20 staining helps pathologists determine whether abnormal lymphoid cells originate from B-cells, which is essential for accurate diagnosis and targeted treatment planning.

Benefits of the Test

• Helps diagnose B-cell lymphomas and leukemias
• Assists in identifying B-cell lineage in tumors
• Supports classification of hematological malignancies
• Improves diagnostic accuracy in lymphoid disorders
• Helps guide targeted therapy and treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CD20 test when there is suspicion of lymphoma, leukemia, or abnormal lymphoid proliferation. It is commonly used in:

• Diagnosis of non-Hodgkin lymphoma
• Evaluation of enlarged lymph nodes
• Bone marrow biopsy analysis
• Classification of lymphoid malignancies
• Oncology and hematopathology investigations

CD20 is often used along with other markers such as CD3, CD5, CD10, CD79a, BCL-2, and Ki-67 to achieve precise tumor classification and immunophenotyping.

Preparation Before Test

No special preparation is required from the patient. Important considerations include:

• The test is performed on a biopsy or bone marrow tissue sample
• No fasting or medication restrictions are needed
• Previous pathology reports and clinical history may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected lymphoma or leukemia
• Individuals with persistent lymph node enlargement
• Cases requiring B-cell tumor classification
• Patients undergoing bone marrow biopsy evaluation
• Oncology patients requiring immunohistochemistry profiling

The IHC CD20 test is an essential diagnostic tool in hematopathology and oncology. By identifying B-cell-specific antigen expression, it helps clinicians accurately diagnose lymphoid malignancies and plan effective targeted therapies.